Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9615 posts found.

amgen_flag

Amgen showcases positive Phase III multiple myeloma drug at ASCO

June 7, 2016 Manufacturing and Production, Research and Development ASCO, Amgen, Kyprolis, dexamethasone, lenalidomide, multiple myeloma

Amgen (NASDAQ: AMGN) has presented data showing a statistically significant increase in progression-free survival and overall response rate in multiple …
News
novartis_outside_1

Novartis says Phase II data for rare lung cancer showed overall response rate of 63%

June 7, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist

Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …
News
test_results

Pivotal avelumab data in Merkel cell carcinoma presented at ASCO

June 6, 2016 Manufacturing and Production, Research and Development ASCO, Merck, Pfizer, avelumab, merkel cell carcinoma

New data presented at the American Society of Clinical Oncology’s annual general meeting has shown that avelumab, an investigational anti-PD-L1 …
News
abbvie_0

AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials

June 6, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
News
abbvie_0

AbbVie says Stemcentrx’ stem cell drug shows some benefits in early trials

June 6, 2016 Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t

US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
News

Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial

June 6, 2016 Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab

Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …
News
stocks1

Weekly Movers: Relypsa, Titan Pharma, Allergan…

June 6, 2016 Research and Development, Sales and Marketing Stock, drug trial, research, stock market

The prestigious ASCO meet is underway and results of new drug trials will be a key stock mover over the …
Feature

Trial data shows promise for Lilly/MSD combo regimen in lung cancer

June 6, 2016 Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship

Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …
News
opdivo_1

Bristol-Myers Squibb presents Opdivo data at ASCO

June 6, 2016 Research and Development, Sales and Marketing ASCO, Bristol-Myers Squibb, opdivo

Bristol-Myers Squibb (NYSE: BMY) has presented a wide range of results on Opdivo (nivolumab) in a range of oncology indications …
News
janssen_latest_logo_on_sign_closer

Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS

June 6, 2016 Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma

Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival.  The company …
News

Roche says Phase III trials for giant cell arteritis drug met primary endpoint

June 6, 2016 Research and Development, Sales and Marketing Roche, arthritis, drug trial

Cancer drugmaker Roche (SIX: ROG) said late stage trials for its drug to treat giant cell arteritis (GCA) met its …
News
sample

Sanofi and Regeneron combo shows superiority in late-stage atopic dermatitis trials

June 6, 2016 Research and Development, Sales and Marketing Dupilumab, Regeneron, Sanofi, atopic dermatitis, late stage trials

Sanofi (NYSE: SNY) and Regeneron (NASDAQ: REGN) have announced positive results from a Phase III trial evaluating dupilumab in patients …
News
novo_flag

Novo Nordisk presents positive long-term results for Saxenda

June 3, 2016 Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss

Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …
News
shire_image_4

Shire completes Baxalta takeover

June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Baxalta, Shire, deal, merger and acquisition, revenue, sales

UK drugmaker Shire (LSE: SHP) on Friday announced the completion of merger with rare disease specialist Baxalta (NYSE: BXLT).  The …
News

Bayer, Orion to start Phase III trials for prostate cancer drug

June 3, 2016 Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research

German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
News
The Gateway to Local Adoption Series

Latest content

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026

Study explores speech as marker in rare neurodegenerative disease

April 27, 2026

Ofichem brings all brands under single trading name

April 23, 2026